Amman, 18 March 2013 - Hikma Pharmaceuticals today announces the signing of an exclusive ten-year collaboration and licensing agreement with Sinclair IS Pharma for Flammacerium, its leading hospital product for the prevention and treatment of infections from severe burn wounds, in the Middle East and North Africa ("MENA") region.

Flammacerium is a sterile topical cream for the treatment and prevention of infections in extensive burn wounds.  The product is a silver sulfadiazine cream with cerium nitrate to reduce the occurrence of immunosuppression which can occur in severely burned patients.  Under the terms of the agreement, Hikma will have the exclusive rights to register and market Flammacerium in 18 countries across MENA. 

Said Darwazah, Hikma's CEO said, "A key part of our MENA strategy is to continue expanding our network of global alliances to support us in strengthening our product portfolio.  We are pleased to be partnering with Sinclair to bring Flammacerium, an excellent product which will strengthen our dermatology portfolio, to our patients in the MENA region." 

Chris Spooner, CEO of Sinclair IS Pharma said, "This collaboration further demonstrates Sinclair's ability to move our product portfolio into fast-growing emerging markets through regional partnerships.  Hikma's presence and reputation across the MENA region will enable us to rapidly progress the adoption of Flammacerium."

About Hikma
Hikma Pharmaceuticals PLC is a fast growing global pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.  As of December 2012, Hikma had a total of 6,521 employees.

About Flammacerium
Flammacerium is a sterile topical cream for the treatment and prevention of infections in extensive burn wounds. The product is a silver sulfadiazine cream with cerium nitrate to reduce the occurrence of immunosuppression which can occur in severely burned patients.  It was approved in 1983 and is available in more than 50 countries.  Flammacerium does not have patent protection but barriers to entry limit competition.  It is used mainly in hospitals and specialist clinics.

About Sinclair IS Pharma
Sinclair IS Pharma is an international specialty pharmaceutical company centred on dermatology; in particular aesthetics, wound care, and skin care.  The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.

For further information:
HIKMA Pharmaceuticals
Name: Hana Ramadan, Dana Shekem
Email: hramadan@hikma.com, dshekem@hikma.com
Tel: (+962) 6 5802900 Ext. 313, 311

VARCC - Arabian Communications
Name: Sara Haddadin
Email: sara.haddadin@varcc.com  
Tel: (+962) 6 5547161  Fax:(+962) 6 5547162

© Press Release 2013